Sponsor Dossier
Pharmacor
Sponsor Dossier for Pharmacor. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ADENUBEX
- Brand: AKM
- Brand: AKM-ATORVASTATIN
- Brand: AKM-EZETIMIBE SIMVASTATIN
- Brand: AKM-OLMESARTAN HCTZ
- Brand: AKM-PREGABALIN
- Brand: AL-Cefuroxime
- Brand: ALCEPT
- Device (sponsor): Earwax softening otic solution
About
Pharmacor is an Australian Private Company with ABN 58 121 020 835, registered in New South Wales. The entity is active and GST-registered.
Portfolio
Pharmacor has 133 brands on the ARTG, of which 120 are indexable and 117 carry a Product Information document. 44 brands are PBS-listed, 6 have a PBAC outcome on record, and 1 has an AusPAR on record. Notable brands include ADENUBEX, AKM, AKM-ATORVASTATIN, AKM-EZETIMIBE SIMVASTATIN, AKM-OLMESARTAN HCTZ, AKM-PREGABALIN, AL-Cefuroxime, ALCEPT, ALKEM, ALKEM-AMOXICLAV, ALLERVIC, APEXA.
Therapeutic focus
— Cardiology: 34 brands — Infectious Disease: 16 brands — Immunology: 12 brands — Neurology: 12 brands — Pain Management: 10 brands — Endocrinology: 9 brands — Psychiatry: 8 brands — Gastroenterology: 7 brands — Musculoskeletal: 7 brands — Reproductive Health: 5 brands — Dermatology: 5 brands — Oncology: 2 brands — Respiratory: 2 brands — Haematology: 1 brand — Ophthalmology: 1 brand — Other: 1 brand — Complementary Medicine: 1 brand
PBS footprint
44 brands are PBS-listed, with the latest PBS schedule date 2026-10-01.
Regulatory activity
The latest PBAC outcome is 2025-07-01, across 6 brands with a PBAC outcome on record. The latest AusPAR is 2020-08-04, across 1 brand with an AusPAR on record.